Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12 Items
Title  Creator  Group name  Publishing year 
The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases Khellaf et al. EquipeMY 2022-09-08
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2022-12-20
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma Quesada et al. EquipeMY 2022-01
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) Assenat et al. EquipeMY 2021-02-01
FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell Relier et al. EquipeCTCS 2021-03-19
CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM Belthier et al. EquipeMY 2021-10-02
[Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?] Adenis et al. EquipeMY Jan 21, 2020
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27) Samalin et al. EquipeMY May 15, 2020
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure de Meric de Bellefon et al. EquipeJPP 2020-03
Neoadjuvant therapy for gastroesophageal adenocarcinoma Samalin and Ychou EquipeMY Jun 10, 2016
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Assenat et al. EquipeCG May 20, 2015
Bone metastases in gastrointestinal cancer Portales et al. EquipeMY Jan 2015
12 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés